Barry Ticho - Jul 13, 2021 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Chief Medical Officer
Signature
/s/ Stephen Tulipano, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Jul 13, 2021
Transactions value $
-$1,413,654
Form type
4
Date filed
7/15/2021, 07:29 PM
Previous filing
Jun 16, 2021
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Sale -$1.3M -39.9K -22.9% $32.68* 134K Jul 13, 2021 Direct F1, F2, F3
transaction STOK Common Stock Sale -$111K -3.3K -2.46% $33.55* 131K Jul 13, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 430 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2021.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.21 to $34.17 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.